De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times? The bone-modifying agents zoledronic acid, pamidronate, and denosumab have essential ...
Significant unmet needs in SMA management include therapy access, fatigue, reproductive health, and emerging phenotypes in older patients. Intrathecal gene therapy offers potential for older SMA ...
Ivana Rubino works at Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States. Bruce Albala works at Eisai, Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey 07677, United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results